

Thyrocare®

Think Thyroid. Think Thyrocare.

May 20, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

The Bombay Stock Exchange Ltd
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001

Dear Sirs,

Sub: Press Release on Annual Results for the year ended 31-03-2019.

--0--

We are forwarding copy of Press Release on Annual Results of our company for the year ended 31-03-2019.

Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised.

Yours Faithfully,

For **Thyrocare Technologies Limited,**



Ramjee Dorai

Company Secretary and Compliance Officer



Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)

Press Release**Mumbai, 18th May 2019****ANNUAL CONSOLIDATED Revenue OF ₹ 402.91 CRORE, UP 13%***QUARTERLY CONSOLIDATED Revenue OF ₹105.59 CRORE, UP 9%***ANNUAL CONSOLIDATED EBIDTA OF ₹ 160.37 CRORE, UP 9%****QUARTERLY CONSOLIDATED EBIDTA OF ₹36.91 CRORE ****CONSOLIDATED EBIDTA MARGINS 40%****QUARTERLY CONSOLIDATED EBIDTA MARGINS 35% ****ANNUAL STANDALONE Revenue OF ₹ 370.28 CRORE, UP 12%***QUARTERLY STANDALONE Revenue OF ₹97.29 CRORE, UP 8%***ANNUAL STANDALONE EBIDTA OF ₹ 154.28 CRORE, UP 9%****QUARTERLY STANDALONE EBIDTA OF ₹36.53 CRORE ****STANDALONE EBIDTA MARGINS 42%****QUARTERLY STANDALONE EBIDTA MARGINS 38% **** Normalized for one-off adjustments*

Press Release

Thyrocare Technologies Limited (the “company”) today reported its financial performance for the quarter and year ended 31 March 2019.

Annual - Revenues and operational performance

Pathology business grew by 12% with underlying sample growth at 15% and investigations growth at 20%, this after rationalization of certain key profiles under the wellness offerings since mid of May of this calendar year.

The company has processed 18.76 million samples consisting of 101.42 million investigations during the financial year.

Radiology business grew by 33% and number of PETCT scans reported grew at 32%, this despite suspension of operations at Jaipur and Raipur for part of the financial year and operations at Coimbatore and Bangalore commenced only in the last quarter of financial year.

The company reported 29274 PETCT scans during the financial year.

Earnings before interest depreciation and tax (EBITDA)

The normalized EBITDA margins at consolidated level were at 40%. The EBITDA for the financial year is adjusted for one off and non-operating expenditures like, CSR, buyback of share expenses, provision for doubtful debts, one-off payments on cess/ lbt assessment of earlier years and one-off adjustments towards discount entitlement from major vendor.

The normalized EBITDA margins at standalone level for pathology business were at 42%, despite of rationalization in the prices of key wellness profiles. The EBITDA for the financial year is adjusted for one off and non-operating expenditures like, CSR, buyback of share expenses, provision for doubtful debts, one-off payments on cess/ lbt assessment of earlier years and one-off adjustments towards discount entitlement from major vendor.

The EBITDA margins at standalone level for radiology business were at 15%, despite suspension of operations at Jaipur and Raipur for part of the financial year and operations at Coimbatore and Bangalore commenced only in the last quarter of financial year, though the operational costs of these centers continued to accrue.

DISCLAIMER

This media release is for information purposes only and it contains general background information about the company’s activities. The company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, information or events, or otherwise. This media release comprises information given in summary form and does not purport to be complete. This media release should not be considered as a recommendation to any investor to purchase the equity shares of the company. This media release includes statements that are, or may be deemed to be, “forward-looking statements”. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the company, its future financial condition and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the company will be achieved. The past performance is not indicative of future results.